Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7060933 | 0.90 | TSHR (0.42) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7058105 | 0.85 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL5125095 | 0.85 | MEN1 (0.45) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7062949 | 0.84 | LMNA (0.43) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL8807470 | 0.84 | LMNA (0.43) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL10645311 | 0.84 | MAPT (0.44) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL3376659 | 0.84 | CTSV (0.56) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7059598 | 0.82 | VCAM1 (0.52) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL7220724 | 0.82 | SIRT2 (0.46) | ALDH1A1MEN1KMT2ALMNAMAPT | |
| SCHEMBL10642903 | 0.82 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6664263-B2 | Potent unsymmetrical DNA bifunctional intercalators | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-12-16 | — | — | US | disclosed |
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | HEALTH AND HUMAN SERVICES, THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEARTMENT OF | 2003-10-30 | — | — | US | disclosed |
| EP-1265898-B1 | 1,8-NAPHTHALIMIDE IMIDAZO 4,5,1- i de /i ]ACRIDONES WITH ANTI-TUMOR ACTIVITY | US GOV HEALTH & HUMAN SERV (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-0138302-B1 | PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4621086-A | Method of treating leukemia with pyrazolo[3,4,5-kl]acridines | WARNER-LAMBERT COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4588730-A | Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials | WARNER-LAMBERT COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4555572-A | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138302-A1 | Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203916-A1 | 1,8-NAPHTHALIMIDE IMIDAZO{4,5,1-DE}ACRIDONES WITH ANTI-TUMOR ACTIVITY | MKI67, CDKN1A, CCNA1 | ALDH1A1 39/4885MEN1 810/4885KMT2A 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.